Kineta’s ShK-186 Shows Encouraging Early Results as Potential Therapy for Autoimmune Eye Diseases
Thursday, March 19, 2015 | Clinical Trials
Kineta presented encouraging preclinical animal results using ShK-186 in a novel ocular formulation as a topical therapy for autoimmune eye disease, according to a company news release. The results, presented at the 7th Ocular Diseases Drug Discovery Conference, showed topical administration of ShK-186 reduced disease severity and the infiltration of damaging inflammatory cells in an animal model of anterior uveitis. Previous research has also shown that systemic administration of ShK-186 is effective in preventing and treating disease in models of psoriasis, multiple sclerosis, rheumatoid arthritis and autoimmune kidney diseases, among others.
“Initial work with ShK-186 demonstrated that topical administration of the drug to the surface of the eye is well-tolerated and results in significant accumulation in the anterior chamber, inside the eye,” Ernesto J. Muñoz, Associate Director Translational Immunology and Preclinical Development at Kineta, said in a talk at the meeting, according to the news release. “Our work using a model of anterior uveitis, an autoimmune eye disease, shows that ShK-186 is able to prevent disease and inflammatory cell infiltration including T cells expressing the Kv1.3 channel. Blocking effector memory T cells via targeting of Kv1.3 is a novel strategy to treat ocular autoimmune diseases including chronic anterior uveitis, Sjogren’s syndrome and dry-eye disease.”
In these diseases, it was already suspected that inflammation was driven by pathogenic T cells. However, it was not known whether these cells were dependent on Kv1.3 for function.
“In this work, we show that the T cells infiltrating the anterior chamber of the eye express Kv1.3 and are sensitive to treatment with ShK-186. The next step is to validate Kv1.3 as a target in uveitis and dry eye in human patients. This is being done through translational research collaboration with Drs. Cintia De Paiva and Stephen Pflugfelder from the Ocular Surface Center-Baylor College of Medicine,” Dr. Muñoz concluded.
You must be logged in to leave a comment.